Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 2700 of 2873 entries
View as:

Preference of Room Setting and Waiting Time in Patients With Advanced, Locally Advanced, or Metastatic Cancer and Their Caregivers Who Are Seen in the Outpatient Supportive/Palliative Care Center

Phase: N/A Priority: Normal
NCT ID: NCT03671226 Org: User:
Start: 09/28/18 End: 12/31/27 Due: 12/31/28

An Investigational Scan (hpMRI) for Monitoring Treatment Response in Patients With Thyroid Cancer and Other Malignancies of the Head and Neck Undergoing Radiation Therapy and/or Systemic Therapy

Phase: N/A Priority: Normal
NCT ID: NCT04589624 Org: User:
Start: 08/12/20 End: 05/31/27 Due: 05/31/28

Immunotherapy With Chemotherapy and Chemoradiation for Advanced Squamous Cancer of Nasal Cavity / Paranasal Sinuses (I-NAPA)

Phase: N/A Priority: Normal
NCT ID: NCT05027633 Org: User:
Start: 11/02/21 End: 03/30/26 Due: 03/30/27

Neoadjuvant Study of Sequential Eribulin Followed by FAC Compared to Sequential Paclitaxel Followed by FEC in Early Stage Breast Cancer Not Overexpressing HER-2

Phase: N/A Priority: Normal
NCT ID: NCT01593020 Org: User:
Start: 08/03/12 End: 11/04/20 Due: 11/04/21

A Phase II, Single-center, Single-arm Study Evaluating the Safety and Efficacy of Golidocitinib in the Management of Newly Diagnosed Peripheral T Cell Lymphoma Patients (GOLDEN Study) and Correlative Study

Phase: N/A Priority: Normal
NCT ID: NCT06630091 Org: User:
Start: 02/21/25 End: 07/05/29 Due: 07/05/30

Capecitabine and Oxaliplatin in Adenocarcinoma of the Small Bowel and Ampulla of Vater

Phase: N/A Priority: Normal
NCT ID: NCT00354887 Org: User:
Start: 11/30/04 End: 11/30/09 Due: 11/30/10

Dual Time Point FDG PET/MRI Scan in Improving the Imaging Cancer Patients With Brain Metastases

Phase: N/A Priority: Normal
NCT ID: NCT05054998 Org: User:
Start: 08/03/18 End: 04/26/24 Due: 04/26/25

Clofarabine Plus Low-Dose Cytarabine Induction and Decitabine Consolidation in Frontline Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)

Phase: N/A Priority: Normal
NCT ID: NCT00778375 Org: User:
Start: 10/31/08 End: 01/31/15 Due: 01/31/16

High-Dose Gleevec Alone or in Combination With Peg-Intron and GM-CSF in Early Phase Chronic Myelogenous Leukemia (CML)

Phase: N/A Priority: Normal
NCT ID: NCT00050531 Org: User:
Start: 04/30/03 End: 08/31/15 Due: 08/31/16

Project COMBAT: Combating Tobacco Use in the United States Army

Phase: N/A Priority: Normal
NCT ID: NCT00948233 Org: User:
Start: 06/30/09 End: 07/31/16 Due: 07/31/17

Impact of Perioperative Anesthetic Management on Renal Cancer Progression.

Phase: N/A Priority: Normal
NCT ID: NCT06536244 Org: User:
Start: 07/31/20 End: 09/01/28 Due: 09/01/29

M7824 and Eribulin Mesylate in Treating Patients With Metastatic Triple Negative Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03579472 Org: User:
Start: 05/30/18 End: 09/21/22 Due: 09/21/23

Patient Perception of Physician's Compassion, Communication Skills, and Professionalism During an Outpatient Palliative Care Visit

Phase: N/A Priority: Normal
NCT ID: NCT02957565 Org: User:
Start: 11/03/16 End: 01/02/20 Due: 01/02/21

Prostate Conformal Cryotherapy

Phase: N/A Priority: Normal
NCT ID: NCT00877682 Org: User:
Start: 04/06/09 End: 01/14/18 Due: 01/14/19

Phase I/II Study of CD5 CAR Engineered IL15-Transduced Cord Blood-Derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Hematological Malignances

Phase: N/A Priority: Normal
NCT ID: NCT05110742 Org: User:
Start: 04/22/24 End: 12/30/27 Due: 12/30/28

Study of Brentuximab Vedotin Plus TAK228 for Relapsed/Refractory Classical Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma and Other CD30+Peripheral T-Cell Lymphomas

Phase: N/A Priority: Normal
NCT ID: NCT03205891 Org: User:
Start: 03/31/18 End: 03/31/21 Due: 03/31/22

Sunitinib Malate in Patients With Non-Clear Cell Renal Cell Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00465179 Org: User:
Start: 03/31/07 End: 03/31/15 Due: 03/31/16

STRICT - Surveillance With TRoponin During Immune Checkpoint Therapy

Phase: N/A Priority: Normal
NCT ID: NCT06337097 Org: User:
Start: 02/02/24 End: 12/31/28 Due: 12/31/29

Phase Ib Study of AlpeliSib With PEmbroLizumab in Patients With mEtastatic Breast caNcer or melanomA (SELENA)

Phase: N/A Priority: Normal
NCT ID: NCT06545682 Org: User:
Start: 10/15/24 End: 08/03/29 Due: 08/03/30

A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT06237881 Org: User:
Start: 01/31/24 End: 01/01/29 Due: 01/01/30

Venetoclax in Combination With ASTX727 for the Treatment of Treatment-Naive High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT04655755 Org: User:
Start: 01/19/21 End: 07/20/26 Due: 07/20/27

Ultraviolet (UV) Photography in Adolescents

Phase: N/A Priority: Normal
NCT ID: NCT02426853 Org: User:
Start: 04/21/15 End: 09/14/20 Due: 09/14/21

Cisplatin, Docetaxel, and Pembrolizumab in Treating Patients With Stage II-III Laryngeal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04030455 Org: User:
Start: 08/07/19 End: 11/01/25 Due: 11/01/26

Ultra Low Dose Radiation Delivered Before or After Chemotherapy-Free Targeted Therapy in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT04054167 Org: User:
Start: 06/14/19 End: 12/31/25 Due: 12/31/26

Baloxavir and Oseltamivir for the Treatment of Severe Influenza Infection in Immunocompromised Patients

Phase: N/A Priority: Normal
NCT ID: NCT04712539 Org: User:
Start: 10/11/21 End: 02/28/28 Due: 02/28/29